Our results expanded the understanding of glutaminolysis in KRAS-driven cancers by providing GTP for activating KRAS, which suggests that selectively starving cancer cells by reducing GTP, for example, by overexpressing SLC25A21 or inhibiting SCS, is a potential treatment strategy for CRC patients harboring KRAS mutation. The gene discussed is SLC25A21; the disease is cancer.